John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, professor of medicine and oncology, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.
According to Marshall, there are 3 or more medications to choose from when considering third line therapy including regorafenib (Stivarga) and TAS-102 (trifluridine and tipiracil, brand name Lonsurf. This space is also constantly evolving, with promising new combinations from Lonsurf.
It is also important to consider what drugs the patient has been on previously, according to Marshall. All other options, including HER2 should be considered first prior to third line treatment. In summary, it really depends on the patient in front of you. For a patient with a more stable disease, regorafenib may be a good option.